We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Hawkins Inc | NASDAQ:HWKN | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 106.90 | 108.00 | 141.18 | 0 | 08:05:16 |
Second Quarter Fiscal Year 2025 Highlights:
Executive Commentary – Patrick H. Hawkins, Chief Executive Officer and President:
“Our record performance in the second quarter was once again driven by our Water Treatment business, as we continued to gain efficiencies within our recent acquisitions and made progress towards future acquisition targets. Within the quarter we saw strong revenue growth of 23% in our Water Treatment business driven by our recent acquisitions, with organic volume flat due to unfavorable weather conditions in several regions. Revenue in our Industrial segment declined year over year due primarily to reduced selling prices driven by lower commodity costs, with volumes up slightly. Health and Nutrition revenues declined due to lower sales of our manufactured products and overall softness in the market. Overall, we saw 4% revenue growth with gross profit increasing 12%, overcoming the $3.2 million LIFO benefit we saw in the second quarter of fiscal 2024.”
Mr. Hawkins, continued, “Our balance sheet continues to be strong, as we paid down $30 million of debt within the quarter, resulting in our leverage ratio being 0.65x trailing 12-month proforma adjusted EBITDA at the end of the quarter. Looking to the third quarter, we expect continued growth within our Water Treatment segment and for our Health and Nutrition segment to resume growth. We expect to see our Industrial segment continue to perform similar to the first half of fiscal 2025.”
Second Quarter Financial Highlights:
NET INCOME
For the second quarter of fiscal 2025, the Company reported net income of $24.1 million, or $1.16 per diluted share, compared to net income for the second quarter of fiscal 2024 of $23.2 million, or $1.10 per diluted share.
REVENUE
Sales were $247.0 million for the second quarter of fiscal 2025, an increase of $10.5 million, or 4%, from sales of $236.5 million in the same period a year ago. Increased sales in our Water Treatment segment more than offset sales softness in our Industrial and Health and Nutrition segments. Water Treatment segment sales increased $23.6 million, or 23%, to $124.5 million for the current quarter, from $100.9 million in the same period a year ago. Water Treatment sales increased as a result of added sales from our acquired businesses. Industrial segment sales decreased $8.6 million, or 9%, to $89.9 million for the current quarter, from $98.5 million in the same period a year ago. Although overall volumes increased slightly year over year, sales decreased as a result of lower selling prices on certain products, driven by lower raw material costs and competitive pricing actions. Health and Nutrition segment sales decreased $4.5 million, or 12%, to $32.6 million for the current quarter, from $37.1 million in the same period a year ago. Health and Nutrition sales decreased due to lower sales of our manufactured products driven by reduced volumes and selling prices due to decreased demand for certain of our products.
GROSS PROFIT
Gross profit increased $6.3 million, or 12%, to $60.2 million, or 24% of sales, for the current quarter, from $53.9 million, or 23% of sales, in the same period a year ago. During the current quarter, the LIFO reserve was unchanged, having no impact on gross profit. In the same quarter a year ago, the LIFO reserve decreased, and gross profit increased, by $3.2 million. Gross profit for the Water Treatment segment increased $6.3 million, or 22%, to $35.6 million, or 29% of sales, for the current quarter, from $29.3 million, or 29% of sales, in the same period a year ago. Water Treatment segment gross profit increased as a result of increased sales from our acquired businesses. Gross profit for the Industrial segment increased $0.5 million, or 3%, to $18.3 million, or 20% of sales, for the current quarter, from $17.8 million, or 18% of sales, in the same period a year ago. Industrial segment gross profit increased as a result of increased volumes of certain products and product mix changes. Gross profit for our Health and Nutrition segment decreased $0.3 million, or 4%, to $6.4 million, or 20% of sales, for the current quarter, from $6.7 million, or 18% of sales, in the same period a year ago. Health and Nutrition segment gross profit decreased as a result of the decrease in sales.
SELLING, GENERAL AND ADMINISTRATIVE EXPENSES
Selling, general and administrative expenses increased $5.6 million, or 27%, to $26.5 million, or 11% of sales, for the current quarter, from $20.9 million, or 9% of sales, in the same period a year ago. Expenses increased primarily due to $3.8 million in added costs from the acquired businesses in our Water Treatment segment, including amortization of intangibles of $1.5 million. In addition, a year-over-year increase of $1.0 million in compensation expense related to our non-qualified deferred compensation plan increased SG&A expenses, with the offset in other income.
ADJUSTED EBITDA
Adjusted EBITDA, a non-GAAP financial measure, is an important performance indicator and a key compliance measure under the terms of our credit agreement. An explanation of the computation of adjusted EBITDA is presented below. Adjusted EBITDA for the three months ended September 29, 2024 was $46.3 million, an increase of $4.8 million, or 12%, from $41.5 million in the same period a year ago.
INCOME TAXES
Our effective income tax rate was 27% for both the current quarter and for the same period a year ago. The effective tax rate is impacted by projected levels of annual taxable income, permanent items, and state taxes. Our effective tax rate for the full year is currently expected to be approximately 26-27%.
BALANCE SHEET
At the end of the second quarter, our working capital was $18 million higher than the end of fiscal 2024 due primarily to increased inventory and lower liabilities due to the payment of certain year-end accruals in the first quarter. During the quarter, we paid down $30 million on our line of credit. Year-to-date net borrowings of $5.0 million and $59.2 million of operating cash flow was used to fund $25.4 million of acquisition spending for the acquisitions of Intercoastal Trading, Inc. and Wofford Water Service, Inc., capital spending of $21.3 million, stock repurchases of $9.1 million and dividend payments of $7.1 million. Our total debt outstanding at the end of the second quarter was $104.0 million and our leverage ratio was 0.65x our trailing 12-month proforma adjusted EBITDA, as compared to 0.66x of trailing twelve-month adjusted EBITDA at the end of fiscal 2024.
About Hawkins, Inc.
Hawkins, Inc. was founded in 1938 and is a leading specialty chemical and ingredients company that formulates, distributes, blends, and manufactures products for its Industrial, Water Treatment, and Health & Nutrition customers. Headquartered in Roseville, Minnesota, the Company has 61 facilities in 28 states and creates value for its customers through superb customer service and support, quality products and personalized applications. Hawkins, Inc. generated $919 million of revenue in fiscal 2024 and has approximately 1,000 employees. For more information, including registering to receive email alerts, please visit www.hawkinsinc.com/investors.
Reconciliation of Non-GAAP Financial Measures
We report our consolidated financial results in accordance with U.S. generally accepted accounting principles (GAAP). To assist investors in understanding our financial performance between periods, we have provided certain financial measures not computed according to GAAP, including adjusted EBITDA. This non-GAAP financial measure is not meant to be considered in isolation or as a substitute for comparable GAAP measures. The method we use to produce non-GAAP results is not computed according to GAAP and may differ from the methods used by other companies.
Management uses this non-GAAP financial measure internally to understand, manage and evaluate our business and to make operating decisions. Management believes that this non-GAAP financial measure reflects an additional way of viewing aspects of our operations that, when viewed with our GAAP results, provides a more complete understanding of the factors and trends affecting our financial condition and results of operations.
We define adjusted EBITDA as GAAP net income adjusted for the impact of the following: net interest expense resulting from our net borrowing position; income tax expense; non-cash expenses including amortization of intangibles, depreciation and charges for the employee stock purchase plan and restricted stock grants; and non-recurring items of income or expense, if applicable.
Adjusted EBITDA | Three Months Ended | Six months ended | Trailing 12-months ended | |||||||||||
(In thousands) | September 29,2024 | October 1,2023 | September 29,2024 | October 1,2023 | September 29,2024 | |||||||||
Net Income (GAAP) | $ | 24,118 | $ | 23,216 | $ | 52,997 | $ | 46,646 | $ | 81,714 | ||||
Interest expense, net | 1,427 | 717 | 2,690 | 1,865 | 5,107 | |||||||||
Income tax expense | 8,873 | 8,769 | 18,681 | 17,015 | 27,447 | |||||||||
Amortization of intangibles | 3,196 | 1,724 | 5,998 | 3,394 | 11,143 | |||||||||
Depreciation expense | 6,731 | 5,675 | 13,258 | 11,112 | 25,410 | |||||||||
Non-cash compensation expense | 1,832 | 1,260 | 3,299 | 2,219 | 5,960 | |||||||||
Non-recurring acquisition expenses | 94 | 122 | 282 | 122 | 1,077 | |||||||||
Adjusted EBITDA | $ | 46,271 | $ | 41,483 | $ | 97,205 | $ | 82,373 | $ | 157,858 |
HAWKINS, INC. | ||||||||||||||||
CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED) | ||||||||||||||||
(In thousands, except share and per-share data) | ||||||||||||||||
Three Months Ended | Six Months Ended | |||||||||||||||
September 29,2024 | October 01,2023 | September 29,2024 | October 01,2023 | |||||||||||||
Sales | $ | 247,029 | $ | 236,526 | $ | 502,908 | $ | 487,646 | ||||||||
Cost of sales | (186,807 | ) | (182,640 | ) | (378,031 | ) | (381,769 | ) | ||||||||
Gross profit | 60,222 | 53,886 | 124,877 | 105,877 | ||||||||||||
Selling, general and administrative expenses | (26,477 | ) | (20,895 | ) | (51,341 | ) | (40,399 | ) | ||||||||
Operating income | 33,745 | 32,991 | 73,536 | 65,478 | ||||||||||||
Interest expense, net | (1,427 | ) | (717 | ) | (2,690 | ) | (1,865 | ) | ||||||||
Other income (expense) | 673 | (289 | ) | 832 | 48 | |||||||||||
Income before income taxes | 32,991 | 31,985 | 71,678 | 63,661 | ||||||||||||
Income tax expense | (8,873 | ) | (8,769 | ) | (18,681 | ) | (17,015 | ) | ||||||||
Net income | $ | 24,118 | $ | 23,216 | $ | 52,997 | $ | 46,646 | ||||||||
Weighted average number of shares outstanding - basic | 20,757,397 | 20,903,690 | 20,786,938 | 20,905,707 | ||||||||||||
Weighted average number of shares outstanding - diluted | 20,860,418 | 21,026,428 | 20,898,641 | 21,034,153 | ||||||||||||
Basic earnings per share | $ | 1.16 | $ | 1.11 | $ | 2.55 | $ | 2.23 | ||||||||
Diluted earnings per share | $ | 1.16 | $ | 1.10 | $ | 2.54 | $ | 2.22 | ||||||||
Cash dividends declared per common share | $ | 0.18 | $ | 0.16 | $ | 0.34 | $ | 0.31 |
HAWKINS, INC. | ||||||
CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) | ||||||
(In thousands, except share data) | ||||||
September 29,2024 | March 31,2024 | |||||
ASSETS | ||||||
CURRENT ASSETS: | ||||||
Cash and cash equivalents | $ | 7,526 | $ | 7,153 | ||
Trade accounts receivables, net | 115,221 | 114,477 | ||||
Inventories | 81,565 | 74,600 | ||||
Prepaid expenses and other current assets | 5,563 | 6,596 | ||||
Total current assets | 209,875 | 202,826 | ||||
PROPERTY, PLANT, AND EQUIPMENT: | 402,104 | 386,648 | ||||
Less accumulated depreciation | 184,642 | 177,774 | ||||
Net property, plant, and equipment | 217,462 | 208,874 | ||||
OTHER ASSETS: | ||||||
Right-of-use assets | 12,047 | 11,713 | ||||
Goodwill | 111,566 | 103,399 | ||||
Intangible assets, net of accumulated amortization | 123,886 | 116,626 | ||||
Deferred compensation plan asset | 11,698 | 9,584 | ||||
Other | 3,163 | 4,912 | ||||
Total other assets | 262,360 | 246,234 | ||||
Total assets | $ | 689,697 | $ | 657,934 | ||
LIABILITIES AND SHAREHOLDERS’ EQUITY | ||||||
CURRENT LIABILITIES: | ||||||
Accounts payable — trade | $ | 50,956 | $ | 56,387 | ||
Accrued payroll and employee benefits | 12,701 | 19,532 | ||||
Income tax payable | 2,284 | 1,943 | ||||
Current portion of long-term debt | 9,913 | 9,913 | ||||
Environmental remediation | 7,700 | 7,700 | ||||
Other current liabilities | 8,787 | 7,832 | ||||
Total current liabilities | 92,341 | 103,307 | ||||
LONG-TERM DEBT, LESS CURRENT PORTION | 93,862 | 88,818 | ||||
LONG-TERM LEASE LIABILITY | 9,687 | 9,530 | ||||
PENSION WITHDRAWAL LIABILITY | 3,348 | 3,538 | ||||
DEFERRED INCOME TAXES | 21,875 | 22,406 | ||||
DEFERRED COMPENSATION LIABILITY | 13,057 | 11,764 | ||||
EARNOUT LIABILITY | 11,919 | 11,235 | ||||
OTHER LONG-TERM LIABILITIES | 236 | 1,310 | ||||
Total liabilities | 246,325 | 251,908 | ||||
COMMITMENTS AND CONTINGENCIES | ||||||
SHAREHOLDERS’ EQUITY: | ||||||
Common stock; authorized: 60,000,000 shares of $0.01 par value; 20,766,764 and 20,790,261 shares issued and outstanding as of September 29, 2024 and March 31, 2024, respectively | 208 | 208 | ||||
Additional paid-in capital | 31,060 | 38,154 | ||||
Retained earnings | 410,425 | 364,549 | ||||
Accumulated other comprehensive income | 1,679 | 3,115 | ||||
Total shareholders’ equity | 443,372 | 406,026 | ||||
Total liabilities and shareholders’ equity | $ | 689,697 | $ | 657,934 |
HAWKINS, INC. | ||||||||
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) | ||||||||
(In thousands) | ||||||||
Six Months Ended | ||||||||
September 29,2024 | October 1,2023 | |||||||
CASH FLOWS FROM OPERATING ACTIVITIES: | ||||||||
Net income | $ | 52,997 | $ | 46,646 | ||||
Reconciliation to cash flows: | ||||||||
Depreciation and amortization | 19,256 | 14,506 | ||||||
Change in fair value of earnout liability | 684 | — | ||||||
Operating leases | 1,607 | 1,115 | ||||||
Gain on deferred compensation assets | (833 | ) | (48 | ) | ||||
Stock compensation expense | 3,299 | 2,219 | ||||||
Other | (32 | ) | (34 | ) | ||||
Changes in operating accounts providing (using) cash: | ||||||||
Trade receivables | 616 | 4,909 | ||||||
Inventories | (6,403 | ) | 20,752 | |||||
Accounts payable | (4,218 | ) | 6,421 | |||||
Accrued liabilities | (7,285 | ) | (7,149 | ) | ||||
Lease liabilities | (1,624 | ) | (1,127 | ) | ||||
Income taxes | 341 | 990 | ||||||
Other | 811 | 3,430 | ||||||
Net cash provided by operating activities | 59,216 | 92,630 | ||||||
CASH FLOWS FROM INVESTING ACTIVITIES: | ||||||||
Purchases of property, plant, and equipment | (21,286 | ) | (16,922 | ) | ||||
Acquisitions | (25,400 | ) | (3,355 | ) | ||||
Other | 357 | 335 | ||||||
Net cash used in investing activities | (46,329 | ) | (19,942 | ) | ||||
CASH FLOWS FROM FINANCING ACTIVITIES: | ||||||||
Cash dividends declared and paid | (7,121 | ) | (6,535 | ) | ||||
New shares issued | 1,297 | 1,147 | ||||||
Payroll taxes paid in exchange for shares withheld | (2,541 | ) | (2,140 | ) | ||||
Shares repurchased | (9,149 | ) | (9,752 | ) | ||||
Payments on revolving loan | (40,000 | ) | (52,000 | ) | ||||
Proceeds from revolving loan borrowings | 45,000 | — | ||||||
Net cash used in financing activities | (12,514 | ) | (69,280 | ) | ||||
NET INCREASE IN CASH AND CASH EQUIVALENTS | 373 | 3,408 | ||||||
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD | 7,153 | 7,566 | ||||||
CASH AND CASH EQUIVALENTS, END OF PERIOD | $ | 7,526 | $ | 10,974 | ||||
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION | ||||||||
Cash paid for income taxes | $ | 18,340 | $ | 16,025 | ||||
Cash paid for interest | $ | 2,923 | $ | 2,002 | ||||
Noncash investing activities - capital expenditures in accounts payable | $ | 1,094 | $ | 2,970 |
HAWKINS, INC. | |||||||||||
REPORTABLE SEGMENTS (UNAUDITED) | |||||||||||
(In thousands) | |||||||||||
WaterTreatment | Industrial | Health and Nutrition | Total | ||||||||
Three months ended September 29, 2024: | |||||||||||
Sales | $ | 124,528 | $ | 89,936 | $ | 32,565 | $ | 247,029 | |||
Gross profit | 35,590 | 18,268 | 6,364 | 60,222 | |||||||
Selling, general, and administrative expenses | 15,512 | 6,952 | 4,013 | 26,477 | |||||||
Operating income | 20,078 | 11,316 | 2,351 | 33,745 | |||||||
Three months ended October 1, 2023: | |||||||||||
Sales | $ | 100,925 | $ | 98,535 | $ | 37,066 | $ | 236,526 | |||
Gross profit | 29,308 | 17,844 | 6,734 | 53,886 | |||||||
Selling, general, and administrative expenses | 10,145 | 6,806 | 3,944 | 20,895 | |||||||
Operating income | 19,163 | 11,038 | 2,790 | 32,991 | |||||||
Six months ended September 29, 2024: | |||||||||||
Sales | $ | 241,704 | $ | 193,138 | $ | 68,066 | $ | 502,908 | |||
Gross profit | 70,545 | 40,144 | 14,188 | 124,877 | |||||||
Selling, general and administrative expenses | 29,678 | 13,591 | 8,072 | 51,341 | |||||||
Operating income | 40,867 | 26,553 | 6,116 | 73,536 | |||||||
Six months ended October 1, 2023: | |||||||||||
Sales | $ | 194,576 | $ | 219,408 | $ | 73,662 | $ | 487,646 | |||
Gross profit | 55,716 | 37,150 | 13,011 | 105,877 | |||||||
Selling, general and administrative expenses | 19,271 | 13,381 | 7,747 | 40,399 | |||||||
Operating income | 36,445 | 23,769 | 5,264 | 65,478 | |||||||
Forward-Looking Statements. Various remarks in this press release constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements include those relating to consumer demand for products containing our ingredients and the impacts of those demands, expectations for results in our business segments and the timing of our filings with the Securities and Exchange Commission. These statements are not historical facts, but rather are based on our current expectations, estimates and projections, and our beliefs and assumptions. Forward-looking statements may be identified by terms, including “anticipate,” “believe,” “can,” “could,” “expect,” “intend,” “may,” “predict,” “should,” or “will” or the negative of these terms or other comparable terms. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and other factors, some of which are beyond our control and are difficult to predict. Actual results may vary materially from those contained in forward looking statements based on a number of factors, including, but not limited to, changes in competition and price pressures, changes in demand and customer requirements or processes for our products, availability of product and disruptions to supplies, interruptions in production resulting from hazards, transportation limitations or other extraordinary events outside our control that may negatively impact our business or the supply chains in which we participate, changes in imported products and tariff levels, the availability of products and the prices at which they are available, the acceptance of new products by our customers and the timing of any such acceptance, and changes in product supplies. Additional information concerning potential factors that could affect future financial results is included in our Annual Report on Form 10-K for the fiscal year ended March 31, 2024, as updated from time to time in amendments and subsequent reports filed with the SEC. Investors should take such risks into account when making investment decisions. Shareholders and other readers are cautioned not to place undue reliance on forward-looking statements, which reflect our management’s view only as of the date hereof. We do not undertake any obligation to update any forward-looking statements.
Contacts: | Jeffrey P. Oldenkamp | |
Executive Vice President and Chief Financial Officer | ||
612/331-6910 | ||
ir@HawkinsInc.com |
1 Year Hawkins Chart |
1 Month Hawkins Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions